



Date: May 28, 2026

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 Stock Code : INDOCO	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Stock Code : 532612
---	--

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Completion of Inspection at Indoco Remedies Limited Baddi Plant-III

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that German Health Authority (Berlin) had inspected Company's Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi ("Facility"), from April 22, 2026 to April 27, 2026.

The Facility has received EU GMP certification from German Health Authority (Berlin) confirming that Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Please find enclosed herewith press release in this regard.

Kindly take the above information on record.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**



**Ramanathan Hariharan
Company Secretary & Head Legal**



PRESS RELEASE

Indoco's formulation plant at Baddi (Plant III) receives EU GMP certification

Mumbai, May 28, 2026: Indoco Remedies Ltd. has announced today that it received EU GMP certification from the German Health Authority (Berlin) for its Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi, Himachal Pradesh. The inspection was carried out from April 22, 2026, to April 27, 2026.

This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive.

Commenting on this development, **Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd.** said, "The EU GMP certification for our formulations manufacturing plant is a testament to our commitment to delivering high quality products to patients across the globe."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cycloam, Febrex Plus, ATM, Rexitin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media enquiries please contact:

Tel. | +91 22 62871000

E-mail: corpcom@indoco.com